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Aims: Pupillography is a noninvasive and cost-effective method to determine auto-
nomic nerve activity. Genetic variants in cytochrome P450 (CYP), dopamine receptor
(DRD2, DRD3), serotonin receptor (HTR2A, HTR2C) and ATP-binding cassette sub-
family B (ABCB1) genes, among others, were previously associated with the pharma-
cokinetics and pharmacodynamics of antipsychotic drugs. Our aim was to evaluate
the effects of aripiprazole and olanzapine on pupillary light reflex related to
pharmacogenetics.
Methods: Twenty-four healthy volunteers receiving 5 oral doses of 10 mg
aripiprazole and 5 mg olanzapine tablets were genotyped for 46 polymorphisms by
quantitative polymerase chain reaction. Pupil examination was performed by auto-
mated pupillometry. Aripiprazole, dehydro-aripiprazole and olanzapine plasma con-
centrations were measured by high-performance liquid chromatography–tandem
mass spectrometry.
Results: Aripiprazole affected pupil contraction: it caused dilatation after the adminis-
tration of the first dose, then caused constriction after each dosing. It induced
changes in all pupillometric parameters (P < .05). Olanzapine only altered minimum
pupil size (P = .046). Polymorphisms in CYP3A, HTR2A, UGT1A1, DRD2 and ABCB1
affected pupil size, the time of onset of constriction, pupil recovery and constriction
velocity. Aripiprazole, dehydro-aripiprazole and olanzapine pharmacokinetics were
significantly affected by polymorphisms in CYP2D6, CYP3A, CYP1A2, ABCB1 and
UGT1A1 genes.
Conclusions: In conclusion, aripiprazole and its main metabolite, dehydro-aripiprazole
altered pupil contraction, but olanzapine did not have such an effect. Many polymor-
phisms may influence pupillometric parameters and several polymorphisms had an
effect on aripiprazole, dehydro-aripiprazole and olanzapine pharmacokinetics.
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Pupillography could be a useful tool for the determination of autonomic nerve activ-
ity during antipsychotic treatment.
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1 | INTRODUCTION
Aripiprazole (ARI) and olanzapine (OLA) are atypical (second genera-
tion) antipsychotics commonly prescribed for patients with schizo-
phrenia or schizoaffective disorders.1 ARI has partial agonistic activity
at dopamine D2, D3, D4 and serotonin 5-HT1A, 5-HT2C as well as
α1-adrenergic receptors and also exhibits 5-HT2A and 5-HT7 recep-
tor antagonism.2 OLA has higher antagonistic affinity for 5-HT2A
serotonin receptors than for D2 dopamine receptors. Additionally, it
has antagonistic activity at dopamine D3 and D4, serotonin 5-HT3
and 5-HT6, histamine H1, α1-adrenergic, and muscarinic M1–5
receptors.3,4
ARI is extensively metabolized by cytochrome P450 (CYP)
enzymes CYP3A4 and CYP2D6. Dehydro-aripiprazole (DARI), its main
active metabolite, accounts for 40% of the parent compound in
plasma. Moreover, the pharmacological activity of DARI is similar to
ARI.5 Olanzapine is predominantly metabolized by direct
glucuronidation via the UDP-glucuronosyltransferase (UGT) enzyme
family, principally by UGT1A4,6 CYP1A2 and to a lesser extent by
CYP2D6 and CYP3A4.7
Pupillography is a noninvasive and cost-effective method to
determine autonomic nerve activity,8 which was developed in 1958.9
It was thoroughly described that opioid drugs cause pupil constriction
(miosis).10–13
Several atypical antipsychotics caused pupil miosis in overdose
patients. It can be due to inducing unopposed parasympathetic stimu-
lation of the pupil with significant α1-adrenergic receptor blockade.14
By contrast, these drugs could affect the pupil diameter due to their
affinity for dopamine and serotonin receptors15,16 as serotonin and
dopamine are effectors on various types of muscles including the
sphincter pupillae and the dilator pupillae.17 Accordingly, genetic poly-
morphisms present in these genes can affect pupil response.18
The aim of the current study was to evaluate if ARI and OLA
affect pupillometric parameters in healthy subjects after multiple dose
administration. Furthermore, their relationship with pharmacokinetics
and pharmacogenetics was also evaluated.
2 | MATERIALS AND METHODS
2.1 | Study population
A multiple-dose clinical trial including 24 healthy volunteers (12 males
and 12 females) was performed at the Clinical Trials Unit of Hospital
Universitario de La Princesa (Madrid, Spain). The protocol was
approved by the Research Ethics Committee duly authorized by the
Spanish Drugs Agency and under the guidelines of Good Clinical Prac-
tice (EUDRA-CT: 2018–000744-26). All subjects were adequately
informed about the study and, if agreeing to participate, signed an
informed consent form. The trial complied with the international stan-
dards and with the Declaration of Helsinki.
The inclusion criteria were the following: male and female volun-
teers between 18 and 65 years old; free from any known organic or
psychiatric conditions; normal vital signs and electrocardiogram (ECG);
normal medical records and physical examination; no clinically signifi-
cant abnormalities in haematology, biochemistry, serology and urine
tests.
2.2 | Study design
The clinical trial was phase I with multiple oral dose design, open-label,
randomized, crossover, 2-periods, 2-sequences, single-centre and
comparative study performed between June 2018–April 2019. ARI
10 mg/day tablets or OLA 5 mg/day film-coated tablets were adminis-
tered during 5 consecutive days. Block randomization was used to
What is already known about this subject
• Atypical antipsychotics can provoke pupil contraction
due to blocking α1-adrenergic receptors. However, these
drugs could affect pupil diameter due to their affinity for
dopamine and serotonin receptors. Accordingly, polymor-
phisms present in these genes can affect pupil response.
What this study adds
• This study is the first to reveal that aripiprazole has a sig-
nificant influence on pupillary light reflex compared to
olanzapine. Furthermore, several genetic polymorphisms
affect these changes. Therefore, pupillography could be
an important and useful tool to assess autonomic nervous
system activity during antipsychotic drug treatment.
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assign the treatment to each volunteer on the first day.19 The drug
was administered at 09:00 each day under fasting conditions. The
subjects were hospitalized from 1 hour before the first dose until
24 hours after the last dose. In the second period, after a washout
period of 28 days, each volunteer received the opposite drug they
received in the first period. The random allocation sequence, the
recruitment of participants and their assignment to interventions were
performed by investigators of the Clinical Trials Unit.
Twenty-two blood samples were collected from each participant
for pharmacokinetic assessments during each period, thus 44 samples
in total: 7 samples on day 1 (predose and 1, 2, 3, 5, 8 and 12 hours
after dosing); 1 (predose) sample on days 2, 3 and 4; 7 samples on day
5 (predose and 1, 2, 3, 5, 8 and 12 hours after dosing) and 1 sample
on days 6, 7, 9, 11 and 15 (corresponding to 24, 48, 96, 144 and
240 hours after the last dose, respectively). Each blood sample was
labelled with the protocol code, volunteer number, treatment period
and day and extraction time without specifying the administered drug.
Subsequently, the samples were centrifuged at 1900 g for 10 minutes
and then the plasma was collected and stored at −20C until the
determination of drug concentrations.
2.3 | Pharmacokinetic analysis
Plasma concentrations of ARI, DARI and OLA were quantified by a
high-performance liquid chromatography–tandem mass spectrometry
method developed in our laboratory.20
The pharmacokinetic parameters were calculated by
noncompartmental analysis by Phoenix WinNonlin (version
8, Pharsight, Mountain View, CA, USA) as single dose (i.e. for the
first day) and multiple dose (i.e. considering all time points). Peak
plasma concentration (Cmax) and time to reach maximum concentra-
tion (Tmax) were obtained directly from the original data. The area
under the plasma concentration–time curve from time zero to the
last observed time point (AUClast) was calculated using the trape-
zoidal rule. The AUC from time zero to infinity (AUCinf) was deter-
mined as the sum of the AUClast and the extrapolated area
calculated as the last plasma concentration (Clast) divided by the
terminal rate constant (ke) that was determined by regression anal-
ysis of the log-linear part of the concentration–time curve. Elimina-
tion half-life (T1/2) was determined by 0.693/ke. The total apparent
clearance adjusted for bioavailability (Cl/F) was calculated using the
formula: Cl/F = dose/AUCinf. The volume of distribution adjusted
for bioavailability (Vd/F) was calculated as Cl/F divided by ke. AUC
and Cmax were adjusted for dose/weight ratio (AUC/dW and Cmax/
dW, respectively) and were logarithmically transformed for statisti-
cal analysis.
2.4 | Pupillary light reflex measurements
Pupillometric measurements were performed right before and 4 hours
after drug administration on each day of hospitalization. The data
were recorded with a PRL-200 automated monocular infrared
pupillometer (NeurOptics, Irvine, CA, USA). Each measurement was
performed in a hospital room with artificial illumination. In order to
adjust for differences in luminosity, light intensity (in lux) was
measured at the moment of the pupillometric determination.
Before starting the measurement, the subject was instructed to
focus on a small target object with the eye that was not being tested
open (left eye). Stimuli were single light pulses with a fixed intensity
of 180 μW during 154 ms. Once the device was focused on the target
pupil (right eye), a white light stimulus was flashed. The measurements
were sampled at a frequency of 32-frames/s and lasted up to
5 seconds, allowing a full or partial recovery of the pupil size after
light constriction.
Eight different pupillometric parameters were measured based on
the user guide.21 Maximum pupil diameter (MAX) and minimum pupil
diameter (MIN) represent the pupil diameter before constriction and
just at the peak of constriction, respectively. The percentage of con-
striction (CON) was calculated by (MAX – MIN)/MAX. Latency (LAT)
is time of the onset of constriction. ACV and MCV are average and
maximum constriction velocity, respectively. The negative sign differ-
entiates constriction from dilation being the opposite movement.
After reaching its constriction, the pupil tends to recover and dilate
back to its initial resting size, which is measured as average dilation
velocity (ADV). T75 is the total time taken by the pupil to recover
75% of the initial resting pupil size after it reached the peak of
constriction.
2.5 | Genotyping
DNA was extracted from 1 mL of peripheral blood using a MagNA
Pure LC DNA Isolation Kit in an automatic DNA extractor (MagNa
Pure System, Roche Applied Science, Indianapolis, Indiana, USA). Sub-
sequently, it was quantified spectrophotometrically using a NanoDrop
ND-1000 Spectrophotometer (Nanodrop Technologies, Wilmington,
Delaware, USA) and the purity of the samples was determined by the
A260/280 absorbance ratio.
Samples were genotyped with TaqMan assays on an OpenArray
platform on a QuantStudio 12 K Flex instrument. Results were
analysed with the QuantStudio 12 K Flex and the TaqMan Genotyper
softwares (Thermo Fisher Scientific, Waltham, Massachusetts, USA).
The assay included 120 single nucleotide polymorphisms, of
which the following 46 were analysed based on their importance in
the metabolism and mechanism of action of ARI and OLA:
CYP1A2 *1C (rs2069514); *1F (rs762551); *1B 5347 T > C
(rs2470890); CYP2D6 *3 (rs35742686); *4 (rs3892097); *6
(rs5030655); *7 (rs5030867); *8 (rs5030865); *9 (rs5030656);
*10 (rs1065852); *14 (rs5030865); *17 (rs28371706);
*41 (rs28371725); CYP3A4 *22 (rs35599367); *2 (rs55785340); *6
(rs4646438); CYP3A5 *3 (rs776746); *6 (rs10264272); ABCB1 C3435T
(rs1045642); G2677T/A (rs2032582); C1236T (rs1128503); rs3842;
1000-44G > T (rs10276036); 2895 + 3559C > T (rs7787082);
330-3208C > T (rs4728709); 2481 + 788 T > C (rs10248420);
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2686-3393 T > G (rs10280101); 2320-695G > A (rs12720067);
2482-707A > G (rs11983225); 2212-372A > G (rs4148737); ADRA2A
rs1800544; BDNF Val66Met (rs6265); COMT rs4680; rs13306278;
DRD2 TaqIA (rs1800497); 957C > T (rs6277); −141 Ins/Del
(rs1799732); DRD3 Ser9Gly (rs6280); HTR2A T102C (rs6313);
C1354T (rs6314); rs7997012; HTR2C –759C/T (rs3813929);
−697G/C (rs518147); rs1414334; OPRM1 rs1799971; and UGT1A1
rs887829.
Copy number variations in the CYP2D6 gene were determined
with the TaqMan Copy Number Assay (Assay ID: Hs00010001_cn;
Thermo Fisher Scientific, Waltham, MA, USA) which detects a spe-
cific sequence in exon 9.22 Samples were run in the same
instrument.
Since the CYP2D6 *29 (rs16947) polymorphism was not included
in the array, it was genotyped with the same instrument using individ-
ual TaqMan probes. Additionally, the CYP3A4 *20 (rs67666821) poly-
morphism was genotyped by the KASPar SNP Genotyping System
(LGC Genomics, Herts, UK). The ABI PRISM 7900HT Sequence
Detection System (Thermo Fisher Scientific) was used for fluores-
cence detection and allele assignment.23
2.6 | Statistical analysis
Statistical analyses were performed with the SPSS 24.0 software
(SPSS Inc., Chicago, IL, USA). P values ≤.05 were considered signifi-
cant. Hardy–Weinberg equilibrium was estimated for all analysed vari-
ants. Deviations from the equilibrium were detected by comparing
the observed and expected frequencies using a Fisher exact test
based on the De Finetti program (available at http://ihg.gsf.de/cgi-
bin/hw/hwa1.pl).
ANOVA was used to compare mean pharmacokinetic values
according to different categories, e.g. genotype, sex and race. Changes
in pupillometric parameters (MAX, MIN, T75, MCV, CON, ACV, ADV,
LAT) were analysed by repeated measures ANOVA. The values were
adjusted for differences in light intensity (in lux) before analysis.
Repeated measures ANOVA was used to associate pupillometric
parameters to pharmacokinetic parameters and polymorphisms. A
Bonferroni correction was applied for each analysis. Multiple linear
regression models were used to study factors related to all
pupillometric and pharmacokinetic dependent variables.
CYP2D6 genotypes were classified in 4 phenotypes (poor
metabolizer: PM; intermediate metabolizer: IM; normal/rapid
metabolizer: NM and ultra-rapid metabolizer: UM), which is based
on the functionality of alleles24 and according to the standardizing
pharmacogenetic terms consensus.25 CYP3A4 *2, *20, *22 and
CYP3A5 *3 and *6 genotypes were merged into a CYP3A pheno-
type as follows: subjects with at least 1 CYP3A4 reduced activity
allele (i.e. CYP3A4 *1/*22 or *22/*22) and no CYP3A5 activity
(CYP3A5 *3/*3) were considered PM; subjects with normal CYP3A4
activity (CYP3A4 *1/*1) and no CYP3A5 activity (CYP3A5 *3/*3)
were considered IM and subjects with normal CYP3A4 activity
(CYP3A4 *1/*1) and at least 1 CYP3A5 functional allele (CYP3A5
*1/*1 or *1/*3) were categorized as extensive metabolizers (EM).26
Furthermore, a value was assigned to CYP1A2 *1B, *1C and *1F
alleles based on their functionality: 0.5 to *1C, 1 to *1, 1.5 to *1F
and 1.25 to *1B. An activity score was calculated as the sum of
the values assigned to each allele and finally was translated into
phenotypes: NMs and UMs.27
3 | RESULTS
3.1 | Demographic and genotypic characteristics
Ten subjects were Caucasian and 14 were Latin American. The
average age was similar between males and females. Males had
greater weight and height than females; however, the body mass
index values did not differ significantly (Table 1).
Genotype and phenotype frequencies of the analysed variants
are shown in Table S1. HTR2C rs3813929, rs518147, ABCB1
rs4728709, COMT rs13306278, CYP2D6 *14 (rs5030865),
*17 (rs28371706), *3 (rs35742686), *6 (rs5030655), *7 (rs5030867),
*8 (rs5030865), CYP3A4 *2 (rs55785340) and *6 (rs4646438)
were not in Hardy–Weinberg equilibrium (P ≤ .05). The rest of
the polymorphisms were in Hardy–Weinberg equilibrium (P ≥ .05).
Genotype frequencies of ABCB1 rs1128503, rs2032582,
10276036 and rs4148737 and HTR2C rs518147 polymorphisms were
significantly different between males and females (Table S1).
3.2 | Pharmacokinetic analysis
Mean and standard deviation of ARI, DARI and OLA pharmacokinetic
parameters are shown in Table 2. Females had higher ARI T1/2
TABLE 1 Demographic characteristics
n (%) Age (y) Weight (kg) Height (m) BMI (kg/m2)
All 24 (100) 31.5 ± 11.6 71.4 ± 12.2 1.68 ± 0.11 25.3 ± 2.6
Males 12 (50) 28.5 ± 7.4 78.4 ± 12.2 1.76 ± 0.09 25.4 ± 2.8
Females 12 (50) 34.6 ± 14.3 64.3 ± 7.4 1.60 ± 0.07 25.1 ± 2.5
P .104 .003 <.0001 .798
Values are shown as mean ± standard deviation unless otherwise indicated.
BMI, body mass index
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(P = .044) and Vd/F (P = .001) and DARI Vd/F (P = .048) and Cl/F
(P = .015) after multiple dose administration. Moreover, males had
higher DARI AUC24h (P = .035) after single dose administration. No
differences were found in OLA pharmacokinetic parameters between
males and females.
3.3 | The effects of aripiprazole and olanzapine on
pupillary light reflex
Following the first oral administration of ARI, the pupil was signifi-
cantly dilated. Subsequently, on the next 4 drug administration days
ARI caused minor constriction. All pupillometric parameters changed
significantly (MAX: P = .008; MIN: P = .009; CON: P = .013; LAT:
P = .009; ACV: P = .012; MCV: P = .006; ADV: P = .024; T75: P = .015;
Figure 1). OLA showed the same tendency, but only MIN reached the
statistically significant level (P = .046; Figure 1). No differences were
found between males and females regarding any pupillometric
parameters.
3.3.1 | Single dose administration
ARI AUClast and Tmax had an influence on CON (P = .029 and P = .043,
respectively). Moreover, AUClast had an impact on MCV and ADV
(P = .004 and P = .034, respectively; Table 3).
Furthermore, DARI AUC24h had an impact on MAX (P = .042),
MIN (P = .050), CON (P = .047), ACV (P = .049) and MCV (P = .046;
Table 3).
These associations were not confirmed in the multivariate analy-
sis (P > .05). Nonetheless, OLA pharmacokinetics did not have an
effect on any of the pupillometric parameters.
3.3.2 | Multiple dose administration
DARI Cmax had an impact on several pupillometric parameters: MAX
(P = .029), MIN (P = .049), CON (P = .015), ACV (P = .041), MCV
(P = .027), ADV (P = .033) and T75 (P = .045; Table 3). These associa-
tions were not confirmed in the multivariate analysis (P > .05).
TABLE 2 Pharmacokinetic parameters of aripiprazole, dehydro-aripiprazole and olanzapine after administration of a single dose and 5
multiple doses
Aripiprazole All Males Females All Males Females
SINGLE DOSE MULTIPLE DOSE
AUC (ngh/mL)b 724.9 ± 236.5 647.0 ± 197.2 802.7 ± 254.6 11 102.4 ± 8234.0 7790.0 ± 4071.5 14 415.7 ± 10061.4
Cmax (ng/mL) 50.6 ± 15.5 47.7 ± 14.4 53.5 ± 16.6 138.0 ± 45.9 129.6 ± 47.4 146.3 ± 44.9
Tmax (h) 5.2 ± 2.4 4.8 ± 2.8 5.6 ± 2.0 3.2 ± 1.4 3.3 ± 1.4 3.2 ± 1.5
T½ (h) NA NA NA 66.1 ± 24.6 56.1 ± 19.9 76.1 ± 25.5
a
Vd/F (L/kg) NA NA NA 6.0 ± 1.6 5.1 ± 1.0 7.0 ± 1.4a
Cl/F (mL/h/kg) NA NA NA 68.1 ± 21.4 69.1 ± 25.6 67.1 ± 17.5
DEHYDRO-aripiprazole All Males Females All Males Females
SINGLE DOSE MULTIPLE DOSE
AUC24h (ngh/mL) 77.4 ± 43.9 90.3 ± 56.9 64.5 ± 20.6a 5149.8 ± 1628.6 4721.3 ± 1670.3 5578.3 ± 1534.8
Cmax (ng/mL) 5.4 ± 8.5 6.5 ± 5.3 4.3 ± 1.2 34.9 ± 8.5 35.6 ± 9.6 34.1 ± 7.4
Tmax (h) 21.9 ± 4.5 20.9 ± 5.4 22.9 ± 3.4 6.1 ± 4.4 7.1 ± 3.9 5.1 ± 4.8
T½ (h) NA NA NA 107.3 ± 62.5 89.4 ± 45.4 126.9 ± 74.2
Vd/F (L/kg) NA NA NA 40.0 ± 44.0 22.4 ± 10.3 57.6 ± 57.1a
Cl/F (mL/h/kg) NA NA NA 203.5 ± 51.0 181.3 ± 47.3 230.7 ± 44.2a
OLANZAPINE All Males Females All Males Females
SINGLE DOSE MULTIPLE DOSE
AUC (ngh/mL)b 127.6 ± 33.1 127.8 ± 38.6 127.4 ± 28.4 1289.5 ± 370.1 1142.7 ± 291.2 1436.2 ± 393.1
Cmax (ng/mL) 7.9 ± 2.2 7.5 ± 2.0 8.2 ± 2.5 19.1 ± 4.8 18.4 ± 4.0 19.9 ± 5.5
Tmax (h) 5.3 ± 2.3 5.4 ± 2.7 5.3 ± 1.9 4.4 ± 1.7 4.6 ± 1.6 4.3 ± 1.9
T½ (h) NA NA NA 77.1 ± 28.2 79.5 ± 33.4 74.8 ± 23.1
Vd/F (L/kg) NA NA NA 26.6 ± 15.9 26.1 ± 17.2 27.0 ± 15.3
Cl/F (mL/h/kg) NA NA NA 229.7 ± 54.7 218.9 ± 51.9 240.6 ± 57.5
aP ≤ 0.05 vs. males after adjusting for weight. NA: not available.
bfor single dose administration the 24 h area under the concentration–time curve (AUC24h), while for multiple dose administration area under the curve
from zero to infinity (AUCinf) are shown.
Abbreviations: Cmax: maximum plasma concentration; Tmax: time to reach the maximum plasma concentration; AUC: area under the curve; T1/2: half-life;
Cl/F: total drug clearance adjusted for bioavailability; Vd/F: volume of distribution adjusted for bioavailability.
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Nonetheless, ARI and OLA pharmacokinetics did not have any
association with any of the pupillometric parameters.
3.4 | The influence of polymorphisms on
pupillometry
3.4.1 | Aripiprazole
Subjects with the CYP3A IM phenotype had significantly higher MAX
levels than PMs (P = .019). Moreover, HTR2A rs6314 T carriers and
UGT1A1 rs8877829 T/T homozygotes had higher MIN levels than
C/C subjects (P = .025 and .039, respectively). Additionally, subjects
with the CYP3A PM phenotype and DRD2 rs1800487 A2 carriers had
higher CON values than with IM phenotype and A1 carriers,
respectively; however, only CYP3A reached the significant level
(P = .008 and .058, respectively).
Likewise, CYP3A IM and EM subjects, DRD2 rs1800487 A2
carriers, ABCB1 rs10280101 A/A, rs12720067 C/C and rs11983225
T/T subjects had higher LAT values than CYP3A PM subjects, DRD2
rs1800487 A1 carriers and ABCB1 10280101 C, ABCB1 rs12720067
T and ABCB1 rs19983225 C carriers, respectively (P = .020, .039
F IGURE 1 Changes in pupillometric parameters after aripiprazole and olanzapine administration. MAX, maximum pupil diameter, MIN,
minimum pupil diameter; CON, percentage of constriction; LAT, latency; ACV, average constriction velocity; MCV, maximum constriction
velocity; ADV, average dilation velocity; T75, total time taken by the pupil to recover 75% of the initial resting pupil size
TABLE 3 Influence of the pharmacokinetic parameters of aripiprazole and dehydro-aripiprazole on pupillometric parameters
Aripiprazole Dehydro-aripiprazole
Single dose Single dose Multiple dose
Variable AUClast (ngh/mL) Tmax (h) AUC24h (ngh/mL) Cmax (ng/mL)
MAX --- --- P = .042 ## P = .029 ##
MIN --- --- P = .050 ## P = .049 ##
CON P = .029 #" P = .043 ## P = .047 ## P = .015 ##
ACV --- --- P = .049 ## P = .041 ##
MCV P = .004 #" --- P = .046 #" P = .027 #"
ADV P = .034 ## --- --- P = .033 ##
T75 --- --- --- P = .045 ##
The arrows show the relationship between pharmacokinetic and pupillometric parameters. The first arrow refers to the pharmacokinetic parameter, while
the second arrow refers to the pupillometric parameter. #" is indirectly proportional, while ## is directly proportional with the changes.
Abbreviations: MAX: maximum pupil diameter; MIN: minimum pupil diameter; CON: percent of constriction; LAT: latency; ACV: average constriction veloc-
ity; MCV: maximum constriction velocity; ADV: average dilation velocity; T75: total time taken by the pupil to recover 75% of the initial resting pupil size.
Cmax: maximum plasma concentration; Tmax: time to reach the maximum plasma concentration; AUC24h: 24 h area under the concentration–time curve;
AUClast: area under the curve from time zero to the last observed time point.
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and .034, respectively). Moreover, CYP3A PM subjects had lower
ACV and MCV values than IM subjects (P = .028 and .022, respec-
tively). Finally, HTR2A rs6314 T allele carriers had higher T75 levels
than C/C homozygotes, although it did not reach the statistically sig-
nificant level (P = .058).
After performing the multivariate tests, the influence of HTR2A
rs6314 on MIN and T75 remained significant (P = .001 and .020,
respectively; Figure 2).
3.4.2 | Olanzapine
DRD2 rs1800497 A2 allele carriers had higher MAX, ACV and MCV
values than A1/A1 homozygotes (P = 0.025, .043 and .038).
After performing the multivariate tests, the influence of DRD2
rs1800497 on MAX remained significant (P = .039; Figure 2).
3.5 | The influence of polymorphisms on
pharmacokinetics
The univariate and multivariate analyses revealed associations
between ARI, DARI and OLA pharmacokinetic parameters and several
polymorphisms (Tables S2, S3 and S4). Additionally, the results of the
multivariate analysis are shown inTable 4.
3.5.1 | Aripiprazole
Vd/F and Cl/F were notably higher in CYP2D6 UMs than in NMs and
IMs (Vd/F: p = 0.001 and P = .016; Cl/F: P = .016 and .016,
respectively). Additionally, AUCinf and Cmax on days 1 and 5 were sig-
nificantly higher in CYP1A2 UMs than in NMs and RMs (P = .034,
.040 and .012, respectively). Moreover, Cl/F was lower in CYP1A2
UMs compared to the other phenotypes (P = .033). Additionally, Tmax
was higher in ABCB1 rs1045642 TT compared to CC subjects
(P = .033). ABCB1 rs4148737 C/C subjects had 2 times higher T1/2
and Tmax than T carriers (P = .024 and .004). The results are shown in
Table S2. Several of these associations were confirmed in the multi-
variate analysis (Table 4).
3.5.2 | Dehydro-aripiprazole
Cmax was significantly higher in CYP2D6 IM subjects than in NMs and
UMs (P = .006). CYP3A4 PMs had higher AUClast and Cmax than IMs
and EMs (P = .001 and .001, respectively). Additionally, Vd/F was
higher in CYP1A2 UMs than in NMs and RMs (P = .046). Additionally,
Tmax was higher in ABCB1 rs1045642 T/T and lower in ABCB1
rs4148737 C/C subjects compared to the other genotypes (P = .019
and P = .045, respectively). The results are shown in Table S3. Several
of these associations were confirmed in the multivariate analysis
(Table 4).
3.5.3 | Olanzapine
T1/2 was 2 times higher in CYP3A EM subjects compared to IMs and
PMs (P = .025). Additionally, ABCB1 rs10280101 A/A, rs12720067
C/C and rs11983225 T/T subjects had significantly higher T1/2 com-
pared to the other genotypes (P = .046, .046 and .046, respectively).
Finally, UGT1A1 rs887829 T/T homozygotes had higher Tmax than
F IGURE 2 The influence of
HTR2A rs6314 and DRD2
rs1800497 polymorphisms on
pupillometric parameters. (A) The
influence of HTR2A rs6314 on
minimum pupil diameter (MIN)
during aripiprazole treatment.
(B) The influence of HTR2A
rs6314 on total time taken by the
pupil to recover 75% of the initial
resting pupil size (T75) during
aripiprazole treatment. (C) The
influence of DRD2 rs1800497 on
maximum pupil diameter (MAX)
during olanzapine treatment
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C/T heterozygotes and C/C homozygotes (P = .016). The results are
shown in Table S4. Several of these associations were confirmed in
the multivariate analysis (Table 4).
4 | DISCUSSION
4.1 | The influence of sex on pharmacokinetics,
pharmacogenetics and pupillometry
In the current study, ARI and DARI pharmacokinetics were affected
by sex. Females had higher ARI T1/2 and Vd/F than males, which is
consistent with our previous studies.18,28 However, in the present
study females had higher DARI Vd/F and Cl/F and lower AUClast,
which may be explained by the low sample size. Based on previous
studies, Cl/F should be lower in males compared to females.29,30
Nonetheless, no dosage adjustment is recommended for ARI or OLA
despite sex differences because they are predominantly explained by
the differences in body weight.30,31
The differences observed in the prevalence of ABCB1
rs1128503, rs2032582, rs10276036 and rs4148737 polymorphisms
regarding sex may be explained by the reduced sample size.
Regarding HTR2C, it is explained by the location of the gene on
chromosome X.
Some polymorphisms were not in Hardy–Weinberg equilibrium.
Regarding HTR2C, it is due to the location of the gene on chromo-
some X. The disequilibrium for ABCB1 rs4728709 and COMT
rs13306278 could be explained by the small sample size. Regarding
the CYP2D6 and CYP3A4 polymorphisms it is explained by the low
frequency of mutated alleles.
No differences were found between males and females in any of
the pupillometric parameters, which is consistent with previous
studies.18,32
4.2 | Effects of aripiprazole, dehydro-aripiprazole
and olanzapine on pupillometry
The mechanism of action of ARI and OLA is still not perfectly under-
stood.33 ARI and DARI achieve their pharmacological effect possibly
by partial agonistic activity at dopamine D2 and 5-HT1A receptors
and antagonistic activity at 5-HT2A receptors. Pharmacodynamic
effects on receptors other than dopamine D2, 5-HT1A and 5-HT2A
may explain other clinical effects: changes in pupillary light reflex
could be caused by partial agonistic activity at α1-adrenergic recep-
tors.31 Pupil dilatation is primarily an α1-adrenergic receptor-mediated
effect,34 while it is mediated to a lesser extent by dopamine and sero-
tonin receptors.35,36
TABLE 4 Influence of genetic polymorphisms on aripiprazole, dehydro-aripiprazole and olanzapine pharmacokinetic parameters in the
multivariate analysis. Results with P ≤ .05 are highlighted in bold
Aripiprazole
Variable AUC (ngh/mL) Cmax (ng/mL) Tmax (h) T1/2 (h) Cl/F (L/hkg) Vd/F (L/kg)
CYP2D6 phenotype β = −1063.9; P = .049 --- --- β = 16.2; P = .005 β = 15.1; P = .055 β = 1.9; P = .001
CYP1A2 phenotype β = 64555; P = .035 β = 421; P = .044 --- β = 29.3; P = .041 β = −22.1; P = .054 ---
ABCB1 rs1045642 --- --- β = 0.183; P = .738 --- --- ---
ABCB1 rs4148737 β = 58941; P = .026 --- β = .183; P = .545 β = −17.5; P = .027 --- ---
Dehydro-aripiprazole
Variable AUC (ngh/mL) Cmax (ng/mL) Tmax (h) T1/2 (h) Cl/F (L/hkg) Vd/F (L/kg)
CYP2D6 phenotype --- β = 17.3; P = .043 --- --- --- ---
CYP3A4 phenotype β = 4257; P = .273 β = 55.2; P = .005 β = 3.14; P = .015 --- --- ---
CYP1A2 phenotype --- β = 70.5; P = .039 --- --- --- β = 10.2; P = .387
ABCB1 rs1045642 --- --- β = 2.93; P = .021 --- --- ---
ABCB1 rs4148737 --- --- β = −1.99; P = .240 --- --- β = 17.1; P = .041
Olanzapine
Variable AUC (ngh/mL) Cmax (ng/mL) Tmax (h) T1/2 (h) Cl/F (L/hkg) Vd/F (L/kg)
CYP3A4 phenotype --- --- --- β = −17; P = .037 --- ---
ABCB1 rs10280101 --- --- --- β = −26.9; P = .145 --- ---
ABCB1 rs12720067 --- --- --- β = −26.9; P = .145 --- ---
ABCB1 rs11983225 --- --- --- β = −26.9; P = .145 --- ---
UGT1A1 rs887829 --- --- β = 1.58; P = .006 --- --- ---
Abbreviations: CYP: cytochrome p450 oxidase; ABCB1: ATP binding cassette subfamily B member 1; UGT1A1: UDP glucuronosyltransferase family 1 mem-
ber A1; Cmax: maximum plasma concentration; Tmax: time to reach the maximum plasma concentration; AUC: area under the curve; T1/2: half-life; Cl/F: total
drug clearance adjusted for bioavailability; Vd/F: volume of distribution adjusted for bioavailability.
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The dilatation observed after the first ARI administration could be
explained by its partial agonism at these receptors. On the contrary,
OLA is an antagonist at these receptors,3 therefore, it could explain
the lack of pupil dilatation. Both ARI and DARI have higher affinity for
dopamine D2 and 5-HT1A than for α1-adrenergic receptors.37 When
DARI was present, neither ARI nor DARI bound to α1-adrenergic
receptors due to competitive inhibition caused by the higher affinity
for dopamine D2 and 5-HT1A receptors. Hence, a constriction was
observed after drug administration. Our results could confirm the fact
that pupillary changes may rather be caused by the metabolite than
the parent compound.34 This could be the reason why DARI Cmax and
AUClast had an influence on several pupillometric parameters, while
the pharmacokinetic parameters of ARI influenced only a few of them.
In conclusion, ARI and DARI caused changes in pupillary light
reflex due to their unique pharmacological profile. Measuring dynamic
pupillary light reflex is already a valid test for the pharmacodynamic
effects of opioid- and some noradrenergic drugs.38,39 Both drugs cau-
sed pupil constriction in 2 previous studies18,40; however, in another
study, neither ARI nor OLA affected pupil contraction.41 Hence, more
studies are needed to alleviate the ambiguity and they should be
repeated in patients. Afterwards, pupillometry could be introduced in
the practice to assess autonomic nerve activity.
4.3 | Polymorphisms and pupillometry
In previous studies with opioids, CYP2D6 UMs experienced increased
and PMs experienced decreased pupil size compared to EMs.38,39 We
could not replicate these findings with ARI and OLA, which may be
due to their different mechanism of action. Additionally, we did not
find any PM and only 2 UMs were present in our population. Our
results confirm those in our previous study with healthy volunteers
that no associations can be found between CYP2D6 phenotypes and
pupillometric parameters.18
CYP3A phenotypes are unrelated to opioid pharmacokinetics.42
Notwithstanding, in the present study, CYP3A IM pupil size was
increased compared to that of PMs after ARI administration. This
was expected as ARI caused pupil constriction after multiple dose
administration; the pupil was under prolonged ARI exposure in PM
subjects.
The effects of dopamine and serotonin on the pupillary light
reflex are well known. High serotonin levels cause pupil dilatation36
and dopamine may cause pupil dilatation or constriction through sym-
pathetic and parasympathetic nerves, respectively.35 Based on our
results, pupil constriction could be due to the antagonist activity of
ARI at 5-HT2A and 5-HT7 receptors, while its dilatation could be
explained by its partial agonism at dopamine D2, D3, D4 and seroto-
nin 5-HT1A, 5-HT2C receptors.37 This theory was confirmed by our
study: both HTR2A rs6314 and DRD2 rs1800487 had an influence on
the pupil size, the proportion of its change, the time of onset of con-
striction and pupil recovery. Additionally, DRD2 rs1800487 also
affected the pupil size and its constriction velocity after OLA treat-
ment. In our previous study some HTR2A, HTR2C, DRD2 and DRD3
polymorphisms were also related to pupillometric parameters.18 The
lack of associations with HTR2C and DRD3 polymorphisms in the pre-
sent study could be due to the low sample size.
Both ARI and OLA are transported by the P-glycoprotein (P-gp,
ABCB1, MDR1).43 However, to our knowledge, no previous study
could associate the genetic differences in ABCB1 to pupil contraction.
We previously analysed 3 polymorphisms: rs1045642 (C3435T),
rs1128503 (C1236T) and rs2032582 (G2677T/A), but no associations
were found.18 In the current study we analysed 12 ABCB1 polymor-
phisms. No association was found with the 3 previously mentioned
polymorphisms; however, 3 others had an influence on pupil recovery
after ARI treatment. It may suggest that, even though the 3 most com-
mon polymorphisms do not affect the pupillary light reflex, others
could have an influence. Further research including other less studied
ABCB1 polymorphisms should be performed.
UGT1A1 rs8877829 subjects with the mutated T/T genotype had
greater pupil size after ARI treatment. Based on in vitro studies, ARI
does not undergo direct glucuronidation by UGT enzymes31; however,
no sufficient evidence is available thus far. Considering our results,
UGT1A1 may be involved in ARI metabolism.
4.4 | Pharmacokinetics and polymorphisms
Our study confirms the impact of CYP2D6 phenotypes on ARI and
DARI pharmacokinetics.18,44,45 All pharmacokinetic parameters,
except for Tmax, were different in UMs compared to NMs and IMs.
CYP3A only had an impact on DARI and OLA pharmacokinetics,
confirming its involvement in ARI and OLA metabolism.7 The lack of
association with the parent drug, ARI, may be due to the low sample
size, because CYP2D6 and CYP3A4 contribute about equally to the
metabolism of aripiprazole.7 Moreover, CYP3A activity varies predom-
inantly by sex and inhibition or induction of a wide range of sub-
strates, rather than by polymorphisms.46
Based on the literature, ARI is not a substrate of CYP1A2.31
Unexpectedly, in our study, the CYP1A2 phenotype influenced ARI
and DARI pharmacokinetics as UMs showed a lower disposition com-
pared to the other phenotypes. To the best of our knowledge, this is
the first study to report a similar result. Based on our findings, more
studies should be performed to confirm the role of CYP1A2 in ARI
pharmacokinetics.
To date, there are no consistent findings about the role of poly-
morphisms in ABCB1. In our previous studies the C1236T
(rs1128503) polymorphism had an influence on ARI pharmacokinet-
ics.18,47 In the current study, the C3435T (rs1045642) and
rs4148737 polymorphisms were related to ARI and DARI T1/2 and
Cmax—and the rs10280101, rs12720067 and rs11983225 polymor-
phisms had an influence on OLA T1/2 levels. Presumably ABCB1 has
an effect on the pharmacokinetics of these antipsychotics being sub-
strates of P-gp.43 According to our knowledge, no other study
analysed polymorphisms in ABCB1 other than C3435T (rs1045642),
G2677TA (rs2032582), C1236T (rs1128503). More studies are
needed including more polymorphisms in ABCB1 to provide a wider
insight of its role in ARI and OLA pharmacokinetics. Additionally, as
stated previously, the lack of consensus on P-gp pharmacogenetics
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is partially explained by the lack of studies and the guidelines
describing phenotype interference from variants.
Finally, the UGT1A1 rs887829 polymorphism affected OLA phar-
macokinetics. In a previous study, this polymorphism was related to
some adverse effects but not pharmacokinetics.48 OLA is metabolized
predominantly by direct glucuronidation via the UGT enzyme family,7
but clear evidence was found only for UGT1A4.6 Additionally,
UGT1A4 and UGT2B10 polymorphisms significantly contributed to
the interindividual variability in OLA metabolism.49,50 Our study is the
first reporting an association between an UGT1A1 polymorphism and
OLA pharmacokinetics.
4.5 | Study limitations
Only 24 subjects were included in the study, which we consider its
main limitation. Therefore, it is important to interpret these results
with caution: studies including more subjects are necessary to
increase the statistical reliability of the results. Moreover, the pre-
sent study should be repeated in schizophrenic patients, whose
brain structure and genetics may differ from healthy volunteers.
Moreover, neither ARI, nor OLA reached steady state during 5 days
of treatment. Both could have had a greater effect on autonomic
nerve activity if they had reached steady state. However, the Ethics
Committee does not authorize a treatment longer than 5 days with
antipsychotics in healthy volunteers. Accordingly, we cannot apply
pupillometry to assess autonomic disfunction in the clinical practice
yet. Additionally, the Cl/F and Vd/F values were calculated without
knowing the bioavailability, which can yield questionable results,
especially for DARI.
5 | CONCLUSIONS
ARI administration produced pupil contraction: it affected all
pupillometric parameters. After the first dosing it caused dilatation,
which was followed by constriction after each day of treatment. OLA
did not cause any changes in any of the pupillometric parameters.
Additionally, the effects of ARI on the pupil size, the time of onset of
constriction, pupil recovery and constriction velocity were associated
with polymorphisms in CYP3A, HTR2A, UGT1A1, DRD2 and ABCB1
genes. ARI, DARI and OLA pharmacokinetics were significantly
affected by polymorphisms in CYP2D6, CYP3A, CYP1A2, ABCB1 and
UGT1A1 genes. In conclusion, pupillography could be a noninvasive
tool to assess autonomic nervous system activity during antipsychotic
drug treatment.
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